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doi:10.1016/j.ejvs.2009.06.002Abstract Objectives: To evaluate the efficacy of pharmacological interventions in improving
walking capacity and health-related quality of life for people with intermittent claudication.
Datasources: We searched Medline, EMBASE, Cochrane library and relevant websites for
studies published from the start of the databases to February 2009. In addition, reference lists
were manually searched.
Review methods: Based upon a power calculation, only robust (n > 56), peer-reviewed,
double-blinded, randomised and placebo-controlled trials were included.
The main outcomes evaluated were maximal walking distance (MWD) and pain-free walking
distance on a treadmill. Random models were used in the statistical analysis, and chi-square
test were used to test for heterogeneity.
Results: Among 220 trials, only 43 trials fulfilled the quality criteria. Treatment periods,
follow-up and treadmill protocols varied substantially. Vasodilator agents and phosphodies-
terase inhibitors show robust significant results compared to placebo, but the improvements
in MWD are modest. The highest benefit was caused by lipid-lowering agents, which in mean
gained above 160 m in MWD, while the other agents only improved MWD about 50 m.
Conclusion: Several drugs have shown to improve MWD, but with limited benefits. Statins seem
to be the most efficient drug at the moment.
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464 A.H. Momsen et al.Treatment of peripheral arterial occlusive disease (PAD) of Only studies published in peer-reviewed journals werethe lower extremities aims to prevent local progression of
the disease, to relieve clinical symptoms, to improve
quality of daily life and, in general, to avert cardiovascular
morbidity and mortality.
Due to interventional risks and limited potency of
reconstruction, patients with intermittent claudication (IC)
are most often treated conservatively.1 Conservative
treatment should contain all measures of secondary
prevention of cardiovascular diseases, including smoking
cessation, exercise, blood-pressure control, anti-platelet
therapy, dietetic advice and treatment of diabetes and
hyperlipidaemia. Treatment goals include a decrease in
cardiovascular risk and improvement in functional perfor-
mance, including pain-free (PWD) and maximal walking
distances (MWD). Despite considerable treatment efforts,
mortality in IC patients remains high, with a death rate of
20% within 5 years after diagnosis,2 with 80% dying of
cardiovascular events.3e5
Peak exercise performance is only 50% in the IC patient
compared to age-matched controls, equivalent tomoderate-
to-severe heart failure (the New York Heart Association
(NYHA) class IIIeIV). This limitation is particularly detri-
mental to quality of life, and improvement without inter-
vention is rare. Hence, therapy is essential.4 Regular
exercise and smoking cessation reduce the symptoms and
may be preventive for associated cardiovascular disease.6
Efficacy of vasoactive agents, anti-thrombotic agents,
lipid-lowering agents7 and other medications such as
vitamin E,8 omega-fatty acids,9 garlic10 and sex hormones11
have been studied in randomised controlled trials (RCTs).
However, many of the studies are antiquated and do not
fulfil modern criteria for robust studies.
The purpose of the present study is to select the robust
RCTs that evaluate drugs used in the treatment of
moderate IC and perform a pooled meta-analysis of drugs
with similar mode of operation to get a valid estimate of
the effect upon MWD of various classifications of drugs.
Methods
Searching
The Medline (from 1966) and EMBASE (from 1974) were
searched for all RCTs published until February 2009 with no
language restrictions. In addition, bibliographic searches
were carried out using reference lists from retrieved rele-
vant reviews from the past 5 years. The websites www.
vascularweb.org, www.tctmd.com, www.theheart.org,
www.clinicaltrialresults.org were also searched.
Selection
The review comprised prospective, robust, double-blinded,
placebo-controlled, parallel or crossover RCTs, and meta-
analyses studying patients with moderate IC (Fontaine
stage II) and an ankleebrachial pressure index (ABI) of
<0.9. Interventions were pharmacological agents compared
with a placebo control group. Studies that had obtained
patients’ informed consent and had followed the Helsinki
Declaration were included.included. Robust studies were identified by sample size due
to the following power calculation using the formula:
NZ (C2aþ Cb)2 2 CV2/miredif2 (unpaired data), where
NZ number of participants in each group, CVZ coefficient
of variation, miredifZ the minimal relevant difference,
C2a is the alpha fractile in the t-distribution and Cb is the
beta fractile in the t-distribution. A power of 80% gives
CbZ 0.84 and C2aZ 1.96 at a 5% significance level. The
coefficient of variation of repeated test of MWD reportedly
varied from 16%12,13 to 21%.14 Therefore, if miredif is set to
15% and CV 20%, we have: NZ (1.96þ 0.84)2 2 20%2/
15%2Z 28 in each group. Consequently, studies that
comprised <56 patients were excluded (Fig. 1).
Trials without primary outcome measures of either MWD
or PWD were excluded, as were RCTs of phase II, single-
blinded, non-blinded studies and those comparing different
doses or agents without placebo. Trials evaluating surgical
or physical training interventions were also eliminated.
Treadmill tests were used to evaluate walking with
protocols involving either constant or graded loads (most
were 3 km/h).
Secondary outcomes were subjective assessment of
health-related quality of life (QoL) and functional status.
Validity assessment
Two reviewers independently assessed each potentially
relevant study for inclusion. Inter-observer agreement
was established before a trial was included in the review.
We sought information regarding blinding procedures at
treatment and outcome assessment, quality of random-
isation, allocation concealment, description of drop-outs
and withdrawals and intention-to-treat (ITT) analysis.15
In addition, we looked for the presence of a power
calculation and adequate description of statistical
methods.
The data were double-checked by AM. Statistics was
performed by AM and JL using Review Manager 4.2 (The
Nordic Cochrane Centre, Copenhagen, Denmark).
Data extraction
AM reviewed each study and extracted information on: trial
design, degree of blinding, details on patients character-
istics, dosages and treatment periods, outcomes, details on
treadmill test, inclusion and exclusion criteria and addi-
tional quality items to assist in assessing heterogeneity
between studies.
Quantitative data synthesis
Data on the MWD and PWD and secondary outcomes were
recorded for patients receiving active drug compared to
placebo at baseline to study end. We attempted to collect
data from each trial on the means and standard deviations
(SDs) for MWD and PWD; however, this proved difficult
because there were numerous data-reporting inconsis-
tencies. In the meta-analysis, the weighted mean differ-
ence (WMD) in MWD was used to merge and compare results
from the various trials. The data were pooled to obtain an
Potentially relevant studies identified
and screened for retrieval (n=567)
Cochrane reviews (n=10) not in
initial search strategy and studies
identified in Cochrane reviews
(n=12)
Studies retrieved for more detailed
evaluation, full manuscript reviewed
for inclusion (n=220) + 10 Cochrane
reviews 
Studies retrieved for more detailed
evaluation (n=146) + 10 Cochrane
reviews
Studies withdrawn, by abstract
(n=359), inclusive reviews without 
primary data and abstracts only
RCTs excluded (n=74), with reasons
of design (single-blind), outcome
(neither MWD nor PWD),
phase of trial (II), not peer-reviewed 
Potentially appropriate RCTs to be
included in the meta-analysis
(n=63) + 10 Cochrane reviews 
RCTs (n=58) + 10 Cochrane reviews
RCTs (n=43), one meta-analysis and
10 Cochrane reviews with usable
information
RCTs excluded (n=83) with reasons
due to participants less than 56
Studies excluded (n=5) due to
multiple publications of same study,
and reviews about more drugs
RCTs deemed inappropiate for the
systematic review (n=14) due to no
placebo or outcome measure
RCTs deemed inappropiate for the
meta-analysis (n=17) due to no
extractable data for mean walking
distance and standard deviation 
RCTs (n=26) with usable information
for meta-analysis
Figure 1 Flow chart of study selection.
Meta-analysis of Drug Therapy for Claudicants 465overall estimate of the effectiveness of each drug dose as
well as a total estimate of the effectiveness of each type of
drug. These data are presented as a WMD of MWD with
a 95% confidence interval (CI) and a relative improvement.
ITT analysis was performed on all patients randomised to
treatment. We evaluated between-trial heterogeneity
using chi-square test and the overall effect by Z-test.
Results
Trial flow
The search identified 567 potentially relevant studies
and 10 Cochrane reviews, from which 12 studies wereidentified. However, only 220 of the studies were RCTs. Of
these, 74 were excluded due to the design, missing PWD or
MWD, phase II study or not being peer-reviewed publica-
tion, leaving 146 RCTs. Of these, more than half had inap-
propriate sample sizes, other publications turned out to be
duplicates and inappropriate information for the meta-
analysis. This left only 43 robust studies testing different 23
drugs (Fig. 1). Of these, only 26 reported data on MWD with
SD suitable for data extraction for meta-analysis.
Study characteristics
The characteristics of studies included in the systematic
review are presented in Table 1. The drugs tested suitable
466 A.H. Momsen et al.for meta-analysis are shown in Table 2 and were classified
as anti-platelet agents (nZ 5), calcium chelator (nZ 1),
serotonin receptor antagonist (nZ 1), lipid-lowering agents
(nZ 4), phosphodiesterase inhibitors (nZ 4), prostaglan-
dins (nZ 5), proteoglycans (nZ 4) and vasodilators (nZ 2)
(Table 2).Table 1 Study characteristics.
Author Drug (doses) N
Drug
N
Placebo
Follow up
(months)
Hiatt Avasimibe (3) 337 105 12
Wilson L-arginine 66 67 6
Mohler Atorvastatin (2) 240 114 12
Antonicelli ca-heparin 101 100 18
Beebe Cilostazol (2) 346 170 6
Dawson 98 Cilostazol 52 25 4
Dawson Cilostazol 227 239 6
Dawson do cil./pentoxifylline 232
Elam Cilostazol 95 94 3
Money Cilostazol 119 120 4
Strandness cilostazol 265 129 6
Regensteiner Cilostazol (2) 1061 740 6
Gresele Cloricromene 81 78 6
Violi Defibrotide 104 101 12
Guldager EDTA 80 79 6
Hiatt Hydroxytryptamine (3) 326 113 6
Messa heparan sulfate 110 107 6
Creager Iloprost/pentoxifylline 346 84 6
To¨nnesen Indobufen 154 148 6
Kiff inositol nicotinate 40 40 3
Nenci Mesoglycan 120 122 5
Clyne Naftidrofuryl 48 45 6
Adhoute Naftidrofuryl 64 54 6
Kieffer Naftidrofuryl 89 92 6
Adhoute Naftidrofuryl 52 42 6
Lindga¨rde Pentoxifylline 76 74 6
Sanctis Pentoxifylline 60 60 12
Belcaro Pentoxifylline 30 30 6
Cesarone Pentoxifylline 100 100 9
Rudofsky Pentoxifylline 88 88 3 weeks
Porter Pentoxifylline 42 40 6
Brass Phosphodiesterase (2) 256 130 6
Castano Policosanol 27 29 1.5
Hiatt propionyl-L-carnitine 82 73 6
Virgolini Prostacyclin 54 54 1
Diehm Prostaglandin 106 102 3
Lievre Prostaglandin 42 41 3
Mohler Prostaglandin 385 377 0
Lie´vre prostaglandin 209 213 6
Mondillo Simvastatin 43 43 6
Aronow Simvastatin 31 29 12
Mohler Atorvastatin (2) 240 114 6
Coccheri Sulodexide 143 143 7
Arcan Ticlopidine 83 86 6
a Graded: treadmill test at 3.2 km/h, 0% followed by a 3.5% increas
b PWDZ pain-free walking distance, MWDZmaximal walking dista
c Quality of life: measured by either Short form 36, Walking Impair
d n. s.: not significant.
e s.: statistically significant difference between drug and placebo,Previous Cochrane reviews have been performed con-
cerning two vasodilators (buflomedil and naftidrofuryl),
two phosphodiesterase inhibitors (cilostazol and pentox-
ifylline), lipid-lowering agents, prostaglandins, steroid sex
hormones, diet supplementation with omega-3-fatty acids,
Vitamin E, and garlic as well as several meta-analyses withTreadmill test
protocola
Walking testb Quality of lifec
3.2 km/h, >2 min:2% n.s.d n.s.
Graded n.s. n.s.
Graded n.s. MWD n.s.
2.6 km/h, >1 min:4 km/h n.s. PWD
Graded s. s.e
Graded s. s.
Graded s.
s.
Graded s.
Graded s.
Graded s. s.
3.2 km/h, 0% s. s.
3 km/h, 10% n.s. n.s.
s.
n.s. n.s.
Graded n.s. n.s.
3 km/h, 10% n.s. s.
Graded n.s. n.s.
3.2 km/h, 8% s.
var.speed, 10% n.s. MWD
3 km/h, 10% n.s. PWD
3 km/h, 0% n.s. <60 years
3 km/h, 10% s.
3.2 km/h, 12,5% s.
3 km/h, 10% s.
3.2 km/h, 12,5% s.
3 km/h, 12% n.s. MWD
3 km/h, 12% s.
3 km/h, 12% s.
3 km/h, 12,5% s.
3.2 km/h, 7degrees s.
Graded s. s.
3 km/h, 10% s.
Graded s.
2 km/h, 7.5degrees s.
3 km/h, 12% s.
3.2 km/h, 3,2% n.s. MWD
3 km/h, 10% n.s. n.s.
3 km/h, 10% s. s.
3 km/h, 12% s.
3 km/h, 12% s.
Graded n.s. MWD n.s.
3 km/h, 10% s. s.
3.2 km/h, 10% s.
e every 3 min.
nce.
ment Questtionaire or both.
p< 0.05.
Meta-analysis of Drug Therapy for Claudicants 467exercise. The Cochrane reviews identified the first six
mentioned drugs with significant effect on walking distance
(Table 3).
Anti-platelet agents
The meta-analysis included five different drugs: ticlopi-
dine, cloricromene, mesoglycan, indobufen and defibrotide
(Fig. 2). The effect estimate was positive though not
statistically significant in all studies. The overall pooled
estimate was in favour of treatment, but with a modest
increase in MWD of 59 m (95% CI: 37e81 m).
The most promising on the individual drugs was indo-
bufen, with an estimated increase in WMD of 98 m
(nZ 302).16
Calcium chelator and serotonin receptor antagonist
Ethylenediaminetetraacetic acid (EDTA) chelation therapy
for atherosclerosis was studied in one RCT (nZ 153). The
placebo group’s improvement was found 1.1-fold better
with regard to both PWD and MWD than that of the EDTA-
treated group.17
One study evaluated AT-1015, a serotonin receptor
antagonist.18 The study arm with highest drug dose was
prematurely closed due to an excess number of non-fatal
myocardial infarctions. In addition, the authors concluded
that selective serotonin receptor blockade did not improve
exercise tolerance or QoL.18
Lipid-lowering agents
The studies of lipid-lowering agents included four different
drugs: atorvastatin, simvastatin, policosanol and
avasimibe.
Statins
Mohler studied 10 mg and 80 mg of atorvastin, but failed
successful randomisation of patients receiving the highest
dose of 80 mg because the intervention group had signifi-
cantly lower walking distance at baseline compared to the
controls, so we excluded this group in the meta-analysis.
Using 10 mg, the increase in MWD was 56 m (95% CI:
52e59 m).19
In two studies testing simvastatin (doses of 750, 250 and
50 mg) the MWD increased significantly (104 m (95% CI:
62e147 m)). Aronow showed a 42% increased exercise time
after 1 year treatment, and in Mondillo’s study an increase
was already seen at 3 months and even greater at 6 months
with 90 m more PWD and 126 m more MWD in the simvas-
tatin group.20,21
Policosanol
In a 2-year follow-up study, policosanol showed significant
results of PWD, MWD, ABPI and subjective assessments.
Intervention PWD increased 100 m and MWD 314 m
compared to the placebo group.22
Avasimibe
In a study testing the inhibitor of acyl coenzyme A-choles-
terol acyltransferase, Avasimibe, in three doses, there wasa significant effect upon MWD of 154 m (95% CI: 126e182 m)
in the corresponding meta-analysis. The effect estimates of
the individual doses (750, 250 and 50 mg) suggest that the
lower is the most effective.
The effect estimates favoured lipid-lowering agents in
all studies and was statistically significant in all but one
study. The pooled effect estimate in the present meta-
analysis was in favour of intervention with a clinically
relevant increase in MWD of 163 m (95% CI: 83e242 m)
(Fig. 2).
Phosphodiesterase inhibitors
The studies of phosphodiesterase inhibitors included three
different drugs: cilostazol, pentoxifylline and phosphodi-
esterase inhibitor NM-702.
Cilostazol
Studies with cilostazol all showed a significant effect on
walking distance. Doses of 50 and 100 mg have been
examined. MWD increased 36 m (95% CI: 30e41 m) with
50 mg, but almost twice that, 70 m (95% CI: 47e93), with
the 100-mg dose.
The first study to focus on community-based measures of
functional status using the Walking Impairment Question-
naire (WIQ) was Regensteiner’s, who showed a significant
increase in both WIQ, the short form (SF)36 and MWD (95
vs 50 m, 76% vs 20%) compared to placebo.3
Strandness’s study, which was not suitable for the meta-
analysis, showed only significance with the 100-mg dose
(MWD increased 76 m).23
Pentoxifyllin
Our meta-analysis of robust studies included six studies
totalling 788 patients and found a significant increase in
MWD for pentoxifyllin in WMD of 59 m (95% CI: 37e81 m).
The estimated effect varied between 2 and 107 m in the
individual studies similar to estimated effect of doses
(300e1600 mg).
Phosphodiesterase inhibitor NM-702
The phosphodiesterase inhibitor NM-702 has been tested
with the doses 4 and 8 mg. With 4 mg, MWD increased 61 m
(95% CI: 34e87 m), but only 26 m (95% CI: 2 to 53) with the
8-mg dose.
The pooled estimate of all robust phosphodiesterase
inhibitors trials in the meta-analysis was in favour of
treatment with a modest increase in MWD of 49 m (95% CI:
37e61 m).
Prostaglandins
Of five studies of prostaglandins, four were included in the
meta-analysis (Fig. 3).
The pooled estimate was in favour of treatment with
a modest increase in MWD of 66 m (95% CI: 5e128 m) with
a marked signs of heterogeneity among the studies.
Proteoglycans
The studies included three different drugs: heparan
sulphate, calciumeheparin and sulodexide.
Table 2 Mean values of pain-free (PWD) and maximal walking distance (MWD) in m.
Author Anti-platelets N drug PWD mean
(SD)
MWD mean
(SD)
N placebo PWD mean
(SD)
MWD mean
(SD)
DMWDa
Arcan Ticlopidine 83 194 (65) 236 (70) 86 123 (50) 170 (40) 39%
Gresele Cloricromene 81 244 (122) 336 (182) 78 164.4 (116) 309 (145) 9%
Nenci Mesoglycan 120 156 (124) 298 (234) 122 143 (120) 238 (202) 25%
To¨nnesen Indobufen 154 263 (140) 361 (242) 148 153 (87) 263 (140) 37%
Violi Defibrotide 104 351 (171) 101 321 (141) 9%
Calcium chelators
Guldager EDTA 80 97 (47) 180 (150) 79 119 (93) 194 (127) 7%
CNS-stimulators
Hiatt Hydroxytryptamine 326 231 (136) 246 (136) 113 133 (83) 267 (149) 8%
Lipid-lowering agents
Mohler Atorvastatin 80 mg 120 189 (31) 235 (36) 114 142 (11) 260 (22) 10%
Atorvastatin 10 mg 120 187 (27) 316 (36) 22%
Hiatt Avasimibe 750 mg 110 187 (92) 325 (153) 105 165 (92) 288 (146) 13%
Avasimibe 250 mg 113 171 (85) 293 (146) 2%
Avasimibe 50 mg 114 203 (90) 341 (162) 19%
Castano Policosanol 27 334 (29) 649 (54) 29 138 (22) 238 (28) 173%
Mondillo Simvastatin 43 190 (38) 230 (45) 43 100 (34) 104 (29) 121%
Aronow Simvastatin 31 267 (28) 29 184(30)
Phophodiesterase inhibitors
Beebe Cilostazol 100 mg 175 138 (140) 259 (140) 170 96 (140 175 (140) 48%
Cilostazol 50 mg 171 115 (139) 199 (139) 96 (140) 175 (140) 14%
Dawson 98 Cilostazol 100 mg 52 113 (14) 232 (37) 25 85 (14) 152 (24) 52%
Dawson Cilostazol 100 mg 227 218 (149) 350 (209) 239 180 (115) 300 (180) 17%
Pentoxifylline 400 mg 232 202 (139) 308 (183) 180 (115) 300 (180) 3%
Elam Cilostazol 100 mg 95 335 (24) 94 304 (23 10%
Money Cilostazol 100 mg 119 307 (19) 120 268 (19) 15%
Strandness cilostazol 100 mg 133 195 129 141 39%
Cilostazol 50 mg 132 167 141 18%
Regensteiner Cil. (meta-a.) 100 mg 730 210 (143) 350 (214) 740 185 (135) 302 (189) 16%
50 mg 281 123 (125) 220 (296) 95 (70) 161 (129) 37%
Lindga¨rde Pentoxifylline 76 139 (145) 198 (155) 74 126 (120) 200 (138) 1%
Sanctis Pentoxifylline 60 267 (38) 60 188 (19) 42%
Belcaro Pentoxifylline 30 161 (21) 161 (21) 30 103 (22) 103 (22) 56%
Cesarone Pentoxifylline 100 166 (220) 287 (340) 100 155 (440) 180 (120) 59%
Rudofsky Pentoxifylline 88 217 (142) 360 (250) 88 162 (79) 287 (215) 25%
Porter Pentoxifylline 42 195 (171) 268 (199) 40 180 (152) 250 (172) 7%
Brass Phosphodiesterase 8 130 156 (82) 333 (111) 130 126 (64) 272 (103) 22%
4 mg 126 149 (96) 298 (120) 9%
Prostaglandins
Diehm Prostaglandin 106 129 (206) 186 (206) 102 107 (212) 161 (192) 16%
Lievre-96 Prostaglandin 42 270 (280) 428 (461) 41 190 (216) 267 (237) 60%
Mohler Prostaglandin 385 455 (645) 751 (780) 377 487 (695) 795 (847) 6%
Lie´vre Prostaglandin 209 280 (65) 467 (229) 213 245 (71) 378 (240) 24%
Creager Iloprost 266 170 (88) 321 (171) 84 144 (88) 302 (161) 6%
Proteoglycans
Messa Heparan sulfate 110 268 (175) 380 (308) 107 352 (294) 8%
Antonicelli ca-heparin 101 268 (15) 361 (19) 100 237 (15) 321 (19) 12%
Coccheri Sulodexide 143 224 (9) 344 (16) 143 181 (6) 258 (8) 33%
Wilson L-arginine 66 110 (11) 314 (25) 67 146 (12) 392 (28) 20%
Vasodilators
Clyne Naftidrofuryl 48 142 (96) 45 137 (79)
Adhoute Naftidrofuryl 64 416 (274) 54 313 (170)
Kieffer Naftidrofuryl 89 331 (64) 351 (62) 92 208 (63) 231 (63) 52%
Adhoute-90 Naftidrofuryl 52 351 (155) 469 (182) 42 287 (137) 337 (171) 39%
Kieffer Inositol nicotinate 40 197 (126) 40 221 (154) 11%
a DMWD: improvement drug vs placebo.
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Table 3 Results from Cochrane reviews (CR) and meta-analyses on walking distance.
Author Drug (doses (mg)) Trials N total PWD, WMDa
(95% CI)
MWD, WMDb
(95% CI) c
Walking test
outcome
CR 2008, de Backer Naftidrofuryl
(200 3) 6 1083 48.44 (35.94, 60.95)
(200 3) 6 968 1.4 (1.19, 1.6)d
CR 2008, de Backer Buflomedil 2 127 76.92 (32.32, 121.52) 112.64 (27.73,197.54)
CR 2007, Robless Cilostazol
(100 2) 8 1827 31.1 (21.4, 40.9) 49.7 (24.23, 75.18)
(50 2) 3 716 41.3 (7.1, 89.7) 31.9 (12.35, 51.53)
(150 2) 1 104 15,7 (9.6, 41.0) 51.3 (13.92,117.52)
Meta-a.,1996, Hood Pentoxifylline 11 612 29.4 (13, 45.9)
CR 2007, Reiter Prostanoids 5 438 21.34 (20.79, 21.89) 25.69 (25.16, 26.22)
CR 2007, Aung Lipid-lowering agents 7 317 89.76 (30.05, 149.47) 152 (32.1, 271.8)
3 95 7.16 (25.47, 40.39) 23 (69.14, 23.14)
CR 2003, Lip Anti-hypertensive drugs 2 8 (30.66, 46.66) 46 (169.24, 77.24)
CR 2001, Cosmi Anticoagulative drugs 3 66.6 (2.3, 135.5) 122 m vs 53 m,
MWD, n.s.e
CR 2001, Price Steroid sex sshormones 3 109 f
CR 1998, Kleijnen Vitamin E 5 265 f
CR 1997, Jepsen Garlic 1 78 207 m vs 203 m,
PWD, n.s
Exercise
Review 2007, Wind Supervised exercise
vs standard care
81.29 (35.45, 127.14) 155.79 (80.84, 230.74)
Supervised exercise
vs unsupervised
exercise
143.81 (5.81, 281.81) 250.4 (192.35, 308.45)
All 15 761 94.65 (54.78, 134.52) 171.75(106.7, 236.8)
CR 2008, Watson Exercise/usual care 10 250 82.2 (71.7, 92.7) 113.2 (94.96, 131.43)
CR 2007,
Bendermacher
Supervised exercise
vs unsupervised
exercise
8 319 PWD: 0.83g
(0.44, 1.21),
MWD: 0.89
(0.57, 1.21)
a PWD: pain-free walking distance (m), WMD: weighted mean difference (m).
b MWD: maximum walking distance (m), WMD: weighted mean difference (m).
c CI: confidence interval (m).
d Relative improvement ratio.
e n. s.: difference not significant.
f Different tests.
g Overall effect size (6 months).
Meta-analysis of Drug Therapy for Claudicants 469The effect estimate was positive in all studies though
not statistically significant in all the individual studies. The
pooled estimate was in favour of treatment with a modest
increase in MWD of 57 m (95% CI: 16e97 m). Of the indi-
vidual drugs, the effect estimate pointed to sulodexide as
the most effective with an increase in MWD by 86 m (95% CI:
83e89 m).
Vasodilators
Naftidrofuryl
The effect estimate was positive and statistically significant
in three of four studies with naftidrofuryl with effect esti-
mates of 103e133 m in the three positive studies compared
to only 5 m in the non-significant study of Clyne. The pooled
subtotal effect estimate showed an increase in MWD of
90 m (95% CI: 14e166 m) (Fig. 4).Inositol
Only one study (nZ 80) examined 3 months of intervention
with inositol nicotinate and found that the change in MWD
was 24 m (95% CI: 86 to 38 m). The pooled effect esti-
mate in the present meta-analysis was in favour of vaso-
dilator treatment, but with a modest increase in MWD of
59 m (95% CI: 37e81 m).
Discussion
This meta-analysis is based on only robust and peer-
reviewed RCTs in order to avoid the limitations of
pooling small trials, which may be heterogeneous with
regard to outcome measures in meta-analyses and
publication bias.24 We have analysed only primary
outcome as the reliability of the findings of a meta-
analysis is linked to the number of overall events
Figure 2 Meta-analysis of anti-platelet and lipid-lowering agents.
470 A.H. Momsen et al.accrued.24 We followed the QUOROM recommendations
and used well-known criteria when assessing the quality
of trials. Findings suggest that inclusion of reports of
low-quality RCTs in meta-analyses is likely to alter the
summary measures of the intervention effect.25 In
addition, the European methodology guidelines for
design on clinical investigation of medicinal products for
PAD are to be followed.26 Only 42 out of 214 trials ful-
filled the criteria for robust quality trials.
Robust significant findings
To improve walking-distance vasodilator agents (nafti-
drofuryl, buflomedil), phosphodiesterase inhibitors (pen-
toxifyllin, cilostazol) and lipid-lowering agents show robust
significant results compared to placebo, but the changes in
walking distance are relatively modest. The highest benefit
was seen among patients allocated to lipid-lowering agents;
for the most commonly used agent, simvastatin, MWD
improved with approximately 100 m. The clinical improve-
ment comes slowly and patients should expect improve-
ment after months rather than weeks of treatment.27
Statins are advocated to reduce risk of cardiovascular
events. These dual benefits of statins re-enforce their
importance for patients with PAD. Atorvastin andsimvastatin are well-established drugs, while avasimibe was
suddenly withdrawn by Pfizer in 2003.20
Policosanol, as well as statin drugs, works by inhibiting
cholesterol formation in the liver, and it has been touted
as a dietary supplement. However, most studies (>80) are
conducted by a single Cuban research group that owns the
sugarcane policosanol patent. An independent study
published in the Journal of the American Medical Asso-
ciation in 2006 found no benefit on cholesterol profile and
questions the reliability of the Cuban research group.29
Apart from the statins, only two of the drugs (pentox-
ifylline and cilostazol) have received the US FDA approval.30
Theestimatedeffect of pentoxifylline onPWDwasonly in the
order of 60 m. The effect upon QoL has not been evaluated
and, in all studies, it is difficult to support its widespread
use.30 Cilostazol received FDA approval in 1999 and has
significant anti-platelet, vasodilatory capacity and vascular
anti-proliferative properties. The estimated effect of 50 mg
was 36 m and of 100 mg it was 70 m. It has a significant
positive effect on health-related QoL and lipid profile, but
may have side effects in patients with heart failure.30,31
Vasodilators such as naftidrofuryl and buflomedil were
the first class of agents used to treat IC. Naftidrofuryl is
a serotonin antagonist and has been available in Europe
since the 1980s, but not in the US. The improvement of
Figure 3 Meta-analysis of phosphodiesterase inhibitors and prostaglandins.
Meta-analysis of Drug Therapy for Claudicants 471walking distance is approximately 90 m and in three recent
RCTs (nZ 709) 600 mg naftidrofuryl daily significantly
improved aspects of health-related QoL.26
Buflomedil is also only available in Europe and has small
but significant improvement in PWD and MWD.32 The two
studies in the Cochrane review showed significant WMD
(77 m, 113 m), but these results are considered to be
undermined by publication bias due to other inconclusive
and unpublished studies.32
In 2000, De-Backer evaluated the role of orally admin-
istered vasoactive medication in the management of IC in
a meta-analysis of 26 trials with buflomedil, naftidrofuryl
and pentoxifylline, and concluded that none of the prod-
ucts had more than marginally positive effect versus
placebo.33 A large international multicentre RCT (nZ 2078)with mean treatment 33 months investigated buflomedil’s
contribution to reduction of symptomatic cardiovascular
events in patients with PAD, and showed a 26% decrease.
They conclude buflomedil should be considered in addition
to an anti-platelet agent in PAD patients.34 Our meta-
analysis show only a modest increase in MWD, and the
Cochrane review about buflomedil concluded it has only
a narrow therapeutic range.
Prostaglandins cause vasodilatation and inhibition of
platelets aggregation by increasing cyclic adenosine
monophosphate (cAMP). However, daily intravenous
administration is not practical for most patients, so it is
not recommended. Oral prostacyclin analogues exist,
however, beraprost has shown inconsistent results, and
iloprost was recently studied in a multicentre RCT with
Figure 4 Meta-analysis of proteoglycans and vasodilators.
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to placebo.35
A meta-analysis showed that nine studies with PGE1
(nZ 344) increased PWD (107%) and MWD (97%) signifi-
cantly (p< 0.01), and therefore proved the most effective
and best tolerated of all prostaglandins evaluated.36 Our
meta-analysis showed marked signs of heterogeneity, but in
two studies by Lievre et al., WMD was increased by 161 m
(nZ 83) and 89 m (nZ 598), respectively.
Anti-platelet treatment is beneficial in patients with IC
for prevention of future cardiovascular events but has not
been shown to influence claudication distance.37,38 Neither
of the anti-platelets we included is commonly used for
cardiovascular prevention in PAD patients, whereas clopi-
dogrel is approved by the FDA for the secondary prevention
and should always be considered. Clopidogrel, which is
more costly, or low-dose aspirin are the preferred first-line
therapies.38
Limitations
Treadmill testing is notoriously associated with wide intra-
and inter-individual variation, and the protocols included
were either graded or constant, with no or varying slope. Itis likely that such heterogeneous ways of testing imply that
walking distances are not fully comparable. If the study
focusses on longer walking distance (>100 m as suggested
by the EU agency for IC trials) both test protocols can be
used with comparable reliability.39
This meta-analysis and all reviews of class C04A drugs,
except the Cochrane review concerning naftidrofuryl, were
based on published aggregate data, which is the dominant
method and a valuable approach for synthesising efficacy,
but it has several drawbacks. We found insufficient infor-
mation such as missing standard deviation, and confidence
interval may be provided for baseline and final values, but
not for themean change. In all, in spite of attempts to obtain
the missing information from the authors, only 26 of the 43
relevant studies could be included in the meta-analysis.
The overall pooling of data in various drug classifications
was performed in order to analyse the value of the physi-
ological target of the drug. However, this strategy risk that
a specific drug with benefit are judged without benefit, and
vice versa. Consequently, subgroup analyses were per-
formed concerning the specific drug.
Improved MWD is found to correlate with improvement in
quality-of-life instruments such as WIQ and SF-36.3 Unfortu-
nately, assessment of QoL is reported in only 23 of 42 trials,
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these reports (Table 1). Cochrane reviews do not report QoL.
Significant placebo effect is a common feature and can
be explained partly by exercise itself or habituation to
treadmill testing.40
Clinical relevance
Reduction of walking distance reduces the activities of
daily living linked with a person’s autonomy, influences
social life and quality of life. European guidelines suggest
at least 30% increase from baseline in both PWD and MWD.
In patients with a baseline MWD at 200 m, an improvement
of 100 m (þ50%) is considered clinically meaningful to help
maintain essential activities of daily living.32 The ability to
walk about 70 m without pain enables patients to work in
a non-physical job, participate in most social activities and
be fairly self-sufficient.41
The improvements in MWD for the clinically most
important drugs in our meta-analysis was for simvastatin
(þ104 m), atorvastatin (þ56 m), cilostazol (þ69 m), indo-
bufen (þ98 m) and naftidrofuryl (þ90 m). Besides their
effect upon MWD, statins are important in relation to
reducing the risk of cardiovascular morbidity and mortality.
Clinical relevance in relation to QoL is particularly
focussed on pain and limitations in activities of daily
living,26 whereas an increase in walking distance may not
be subjectively appreciated by the patient.
Suggestions to future research
From a medical and socio-economic point of view, the PAD
complication rate and related treatment costs must be
reduced to the lowest possible level. With the ageing
population and the increasing prevalence with age, there is
a growing need for optimal medical management across all
specialties treating patients with PAD. Structured regular
exercise and smoking cessation is the most important non-
pharmacological ways to prevent cardiovascular events,
improve the walking distance and quality of life, and has to
be complemented with statins and anti-platelet
medication.
Although exercise therapy is considered to be of signif-
icant benefit to people with IC, almost half of those
affected do not undertake any exercise therapy.6 In addi-
tion, compliance with supervised exercise is poor, and in
practice, compliance with smoking cessation and medical
treatment is also poor and most people remain symptom-
atic with consequently impaired quality of life.37 There-
fore, development of additional therapies is needed, and
strict trials should also examine issues of cost and QoL.42 A
national consensus conference, based on a recent Cochrane
review, concluded that health resources should be allo-
cated to prevention, rehabilitation and physical exercise
rather than to reimbursement of these products with
doubtful efficacy.43,44
Therefore, the key questions remain, if particular drugs
have synergistic interactions with physical exercise and
smoking cessation, and how to educate the patients to take
responsibility in their own smoking cessation and rehabili-
tation with exercise.Conclusion
This systematic review and meta-analysis of robust RCTs
shows that pharmacological management of IC remains to
be defined precisely, as of yet there have been very few
significant pharmacological breakthroughs in the treat-
ment. Pooled effect estimates revealed modest improve-
ments of walking distance for anti-platelets, vasodilator
agents as naftidrofuryl, phosphodiesterase inhibitors such
as cilostazol and pentoxifylline, prostaglandins and
proteoglycans. However, their role remains controversial.
Statins showed the highest benefit in walking and, in
addition, it reduces the risk of cardiovascular morbidity and
mortality. However, statins do not cure claudication, and
improvement of walking distance is associated with
improved quality of life, consequently, additional trials to
develop therapies are needed.
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